Congressman Tim Kennedy (NY-26) announced $7,731,872 in new federal funding for Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National Institutes of Health’s (NIH) Research Facilities Construction Grants.

As the American Society for Radiation Oncology gathers for its annual meeting, a radiation oncologist from Roswell Park is highlighting new evidence that a single dose, or “fraction,” of radiation therapy may be as effective as multiple radiotherapy treatments in addressing lung cancer tumors located centrally in the lung.

The Clinical Leukemia Service at Roswell Park helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML). The results of the KOMET-001 study, published today in The Lancet Oncology, show that the drug — part of a class of targeted therapies known as menin inhibitors — produced a partial or complete response in about a third of patients, all of whom had received two or more prior therapies.